BioInvent announces new clinical trial collaboration with Merck

3 April 2024

Swedish immuno-oncology specialist BioInvent International (Nasdaq Stockholm: BINV) announced a clinical trial collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co (NYSE: MRK) for a Phase I/IIa study of its monoclonal antibody BI-1910 in combination with the US pharma giant’s blockbuster cancer drug Keytruda (pembrolizumab).

Under the terms of the supply accord, MSD will provide its anti-PD-1 therapy Keytruda to be used in combination with BI-1910. The Phase I/IIa trial will be conducted in the USA and Europe and has an innovative, adaptive design to allow for ideal dose escalation.

BioInvent noted that BI-1910 is the firm’s second tumor necrosis factor receptor 2 (TNFR2) program to enter clinical development, after BI-1808 currently in Phase IIa. BI-1910 displays a differentiated, agonist approach to cancer treatment compared to BI-1808, BioInvent’s first-in-class anti-TNFR2 antibody that is currently also being trialled in combination with Keytruda for lung cancer and ovarian cancer patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK